ACE2 receptor, cytokine storm, ARDS, and therapeutic approaches
SARS-CoV-2 binds the ACE2 receptor on human cells via its Spike protein, requiring TMPRSS2 (a transmembrane serine protease) as an activator. The Spike protein of SARS-CoV-2 shares ~76% amino acid identity with SARS-CoV(1) but exhibits at least 10-fold stronger affinity for ACE2, partly explaining its higher infectiousness.
The viral replication cycle follows the pattern established by SARS-CoV(1): endocytosis of the Spike–ACE2 complex, conformational change facilitating envelope fusion, release of the RNA payload, hijacking of the cell’s biomolecular factory, auto-assembly of new virions, and exocytosis. The infected cell is not immediately killed — it is diverted into a virus production factory until eventual apoptosis.
ACE2 normally cleaves Angiotensin-2 (a vasoconstrictor) into Angiotensin-1(1-7) (a vasodilator), lowering blood pressure. Patients taking ACE1 inhibitors may overexpress ACE2 — creating more entry points for the virus. Additionally, viral consumption of ACE2 through endocytosis reduces its availability for blood pressure regulation.
ACE2 and TMPRSS2 are ubiquitous membrane proteins, particularly abundant in lung and small intestine epithelia, endothelial vascular cells, liver, kidney, and potentially brain tissue. This explains the diverse clinical presentations of COVID-19: viral pneumonia, diarrhea, anosmia, ageusia, and potential neurotropism.
Phase 0 — Incubation (~5.1 days median): viral replication in lung cells, patients asymptomatic but potentially contagious 24 hours before symptom onset.
Phase 1 — Flu-like presentation (~7 days): fever (77%), cough (81%), fatigue (52%). Approximately 18% of patients remain fully asymptomatic. Reduced viral load exposure (masks, distance) correlates with less severe presentation.
Phase 2 — ARDS (~20% of symptomatic cases, days 7-10): ground-glass opacity on CT imaging, SaO₂ below 70%, requiring mechanical ventilation or ECMO in the most severe cases.
The immune exacerbation follows a destructive cascade: infected cells produce Type I interferon, activating macrophages that release pro-inflammatory cytokines (IL-1β, IL-6, TNF-α), which recruit additional immune cells that amplify the inflammatory signal. Simultaneously, CD4+ and CD8+ lymphocytes are rapidly depleted — removing the very cells responsible for modulating the immune response.
This positive feedback loop leads to sepsis, disseminated intravascular coagulation, multi-organ failure, and potentially death. Early lymphocyte counts, IL-6 levels, and viral RNAemia are candidate biomarkers for predicting clinical deterioration before ARDS onset.
The article maps therapeutic strategies to specific points in the viral lifecycle: monoclonal antibodies targeting the Spike protein, TMPRSS2 inhibitors (Nafamostat, Camostat), hydroxychloroquine (endocytosis inhibition + cytokine regulation), Lopinavir/Ritonavir (protease inhibition preventing virion assembly), and Remdesivir (RNA-dependent RNA polymerase inhibition). The WHO SOLIDARITY trial was designed to evaluate these candidates under rigorous clinical conditions.